EQUITY RESEARCH MEMO

VIDA Diagnostics

Generated 5/9/2026

Executive Summary

Conviction (model self-assessment)60/100

VIDA Diagnostics is a private company based in Coralville, Iowa, founded in 2007, that leverages AI-powered imaging biomarkers to accelerate clinical trials for life-saving therapies. The company’s technology enables data-driven, quantitative analysis of medical images, providing digital biomarkers that help pharmaceutical and biotech firms assess drug efficacy and safety more efficiently. By reducing the time and cost of clinical trials, VIDA plays a critical role in bringing new treatments to patients faster. Although the company is not publicly traded and limited financial information is available, its longstanding presence in the diagnostics space and focus on AI-driven solutions position it as a key enabler in the evolving landscape of precision medicine.

Upcoming Catalysts (preview)

  • TBDPotential FDA clearance for new imaging biomarker software60% success
  • TBDStrategic partnership with a major pharmaceutical company50% success
Locked sections
  • · Pipeline Analysis
  • · Competitive Landscape
  • · Catalyst Calendar (full 12-month)
  • · Bull Case
  • · Bear Case
  • · Counterfactual Scenarios
  • · Valuation Notes
  • · SEC Filing Highlights
  • · Insider Activity
  • · Literature Watch
  • · Patent Landscape
  • · Mechanism Cluster Map
  • · Audio Briefing (5 min)